PMID- 25189170
OWN - NLM
STAT- MEDLINE
DCOM- 20151110
LR  - 20211021
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 5
IP  - 5
DP  - 2014 Sep 4
TI  - Maintenance of human amnion epithelial cell phenotype in pulmonary surfactant.
PG  - 107
LID - 10.1186/scrt495 [doi]
LID - 107
AB  - INTRODUCTION: Preterm newborns often require mechanical respiratory support that 
      can result in ventilation-induced lung injury (VILI), despite exogenous 
      surfactant treatment. Human amnion epithelial cells (hAECs) reduce lung 
      inflammation and resultant abnormal lung development in preterm animals; 
      co-administration with surfactant is a potential therapeutic strategy. We aimed 
      to determine whether hAECs remain viable and maintain function after combination 
      with surfactant. METHODS: hAECs were incubated in surfactant (Curosurf) or 
      phosphate-buffered saline (PBS) for 30 minutes at 37 degrees C. Cell viability, phenotype 
      (by flow cytometry), inhibition of T-cell proliferative responses and 
      differentiation into lung epithelium-like cells (assessed with 
      immunohistochemical staining of surfactant protein (SP)-A) were investigated. 
      RESULTS: Cell viability and apoptosis of hAECs were not altered by surfactant, 
      and hAEC phenotype was not altered. hAECs maintained expression of epithelial 
      cell adhesion molecule (EpCAM) and human leukocyte antigen (HLA)-ABC after 
      surfactant exposure. Expression of HLA-DR, CD80 and CD86 was not increased. 
      Immunosuppression of T cells by hAECs was not altered by surfactant. hAEC 
      differentiation into lung epithelium-like cells was equivalent after exposure to 
      PBS or surfactant, and SP-A expression was equivalent. CONCLUSION: Surfactant 
      exposure does not alter viability or function of hAECs. Thus a combination 
      therapy of hAECs and surfactant may be an efficacious therapy to ameliorate or 
      prevent preterm lung disease.
FAU - McDonald, Courtney A
AU  - McDonald CA
FAU - Melville, Jacqueline M
AU  - Melville JM
FAU - Polglase, Graeme R
AU  - Polglase GR
FAU - Jenkin, Graham
AU  - Jenkin G
FAU - Moss, Timothy J M
AU  - Moss TJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140904
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
RN  - 0 (Biological Products)
RN  - 0 (Phospholipids)
RN  - 0 (Pulmonary Surfactants)
RN  - KE3U2023NP (poractant alfa)
SB  - IM
MH  - Amnion/*cytology/drug effects/metabolism
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Biological Products/pharmacology
MH  - Cell Culture Techniques/methods
MH  - Cell Survival/drug effects
MH  - Epithelial Cells/cytology/drug effects/metabolism
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Infant, Newborn
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Phenotype
MH  - Phospholipids/pharmacology
MH  - Pregnancy
MH  - Pulmonary Surfactants/metabolism/*pharmacology
PMC - PMC4169816
EDAT- 2014/09/06 06:00
MHDA- 2015/11/11 06:00
PMCR- 2014/09/04
CRDT- 2014/09/06 06:00
PHST- 2013/12/12 00:00 [received]
PHST- 2014/08/07 00:00 [accepted]
PHST- 2014/09/06 06:00 [entrez]
PHST- 2014/09/06 06:00 [pubmed]
PHST- 2015/11/11 06:00 [medline]
PHST- 2014/09/04 00:00 [pmc-release]
AID - scrt495 [pii]
AID - 392 [pii]
AID - 10.1186/scrt495 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2014 Sep 4;5(5):107. doi: 10.1186/scrt495.